Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
SOX4 Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB, IHC-P, IF, E |
|---|---|
| Primary Accession | Q06945 |
| Other Accession | NP_003098, 4507163 |
| Reactivity | Human, Mouse, Rat |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Calculated MW | Predicted: 52 kDa Observed: 520 kDa |
| Application Notes | SOX4 antibody can be used for detection of SOX4 by Western blot at 1 - 2 µg/mL. Antibody can also be used for immunohistochemistry starting at 5 µg/mL. For immunofluorescence start at 20 µg/mL. |
| Gene ID | 6659 |
|---|---|
| Target/Specificity | SOX4; SOX4 antibody is human, mouse and rat reactive. |
| Reconstitution & Storage | SOX4 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. |
| Precautions | SOX4 Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | SOX4 {ECO:0000303|PubMed:8268656, ECO:0000312|HGNC:HGNC:11200} |
|---|---|
| Function | Transcriptional activator that binds with high affinity to the T-cell enhancer motif 5'-AACAAAG-3' motif (PubMed:30661772). Required for IL17A-producing Vgamma2-positive gamma-delta T-cell maturation and development, via binding to regulator loci of RORC to modulate expression (By similarity). Involved in skeletal myoblast differentiation by promoting gene expression of CALD1 (PubMed:26291311). |
| Cellular Location | Nucleus {ECO:0000255|PROSITE-ProRule:PRU00267, ECO:0000269|PubMed:16631117} |
| Tissue Location | Testis, brain, and heart. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
SOX4 is a member of the SOX (SRY-related HMG-box) family of transcription factors involved in the regulation of embryonic development and in the determination of the cell fate (1,2). It may act as a transcriptional regulator after forming a protein complex with other proteins, such as syndecan binding protein (syntenin) (3). SOX4 contains one HMG box DNA-binding domain and may function in the apoptosis pathway leading to cell death. It has also been suggested to play a role in tumorigenesis and may mediate downstream effects of parathyroid hormone (PTH) and PTH-related protein (PTHrP) in bone development (4,5).
References
Wotton D, Lake RA, Farr CJ, et al. The high mobility group transcription factor, SOX4, transactivates the human CD2 enhancer. J. Biol. Chem. 1995; 270:7515-22.
Pan X, Li H, Zhang P, et al. Ubc9 interacts with SOX4 and represses its transcriptionalactivity. Biochem. Biophys. Res. Commun. 2006; 344:727-34.
Castillo SD, Matheu A, Mariani N, et al. Novel transcriptional targets of the SRY-HMG box transcription factor SOX4 link its expression to the development of small cell lung cancer. Cancer Res. 2012; 72:176-86.
Zhang H, Alberich-Jorda M, Amabile G, et al. Sox4 is a key oncogenic target in C/EBPa mutant acute myeloid leukemia. Cancer Cell 2013; 24:575-88.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
